H.C. Wainwright Keeps a Buy Rating on Ocular Therapeutix (OCUL)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix (OCULResearch Report) today and set a price target of $9.00. The company’s shares closed last Monday at $3.47.

According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -18.2% and a 28.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aslan Pharmaceuticals Ltd ADR, EyePoint Pharmaceuticals Inc, and Stealth Biotherapeutics Corp.

Ocular Therapeutix has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.

See today’s analyst top recommended stocks >>

Based on Ocular Therapeutix’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $24.45 million. In comparison, last year the company had a GAAP net loss of $15.01 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.